Septic Shock - Pipeline Review, H2 2016

  • ID: 3939698
  • Drug Pipelines
  • 92 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Adrenomed AG
  • InflaRx GmbH
  • Noxxon Pharma AG
  • Orion Oyj
  • Pharmazz, Inc.
  • Therashock, LLC
  • MORE
Septic Shock - Pipeline Review, H2 2016

Summary

‘Septic Shock - Pipeline Review, H2 2016’, provides an overview of the Septic Shock pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Septic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Septic Shock and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note - : Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Septic Shock
- The report reviews pipeline therapeutics for Septic Shock by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Septic Shock therapeutics and enlists all their major and minor projects
- The report assesses Septic Shock therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Septic Shock

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Septic Shock
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Septic Shock pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Adrenomed AG
  • InflaRx GmbH
  • Noxxon Pharma AG
  • Orion Oyj
  • Pharmazz, Inc.
  • Therashock, LLC
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Septic Shock Overview

Therapeutics Development

Pipeline Products for Septic Shock - Overview

Pipeline Products for Septic Shock - Comparative Analysis

Septic Shock - Therapeutics under Development by Companies

Septic Shock - Therapeutics under Investigation by Universities/Institutes

Septic Shock - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Septic Shock - Products under Development by Companies

Septic Shock - Products under Investigation by Universities/Institutes

Septic Shock - Companies Involved in Therapeutics Development

Adrenomed AG

Ferring International Center S.A.

Huons Co., Ltd.

InflaRx GmbH

Inotrem S.A.

Lixte Biotechnology Holdings, Inc.

Noxxon Pharma AG

Octapharma AG

Orion Oyj

Peptinov SAS

Pharmazz, Inc.

Spider Biotech

Takeda Pharmaceutical Company Limited

Therashock, LLC

ViiV Healthcare Limited

XImmune AB

Septic Shock - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

3K3A-APC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adrecizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aspidasept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BC-1215 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-936559 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BTZO-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Sepsis and Septic Shock - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBN-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBN-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBN-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HU-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

L-257 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levosimendan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-6229 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Motrem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOXD-21 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMZ-2010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pooled plasma (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-190 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-056 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selepressin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit TNF-Alpha for Septic Shock - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-14 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Septic Shock - Dormant Projects

Septic Shock - Discontinued Products

Septic Shock - Product Development Milestones

Featured News & Press Releases

Sep 13, 2016: Inotrem Successfully Completes Its First Phase I Clinical Trial with Motrem, a TREM-1 Pathway Modulator for the Treatment of Septic Shock

Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery

Jan 28, 2016: InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody

Oct 08, 2015: Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan

Jun 16, 2015: Tenax Therapeutics Highlights New Scientific Publication Regarding the Potential Mortality Benefits of Levosimendan in Septic Shock Patients

Jan 02, 2013: Adrenomed Develops New Drug To Reduce Mortality From Septic Shock

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Septic Shock, H2 2016

Number of Products under Development for Septic Shock - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Septic Shock - Pipeline by Adrenomed AG, H2 2016

Septic Shock - Pipeline by Ferring International Center S.A., H2 2016

Septic Shock - Pipeline by Huons Co., Ltd., H2 2016

Septic Shock - Pipeline by InflaRx GmbH, H2 2016

Septic Shock - Pipeline by Inotrem S.A., H2 2016

Septic Shock - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016

Septic Shock - Pipeline by Noxxon Pharma AG, H2 2016

Septic Shock - Pipeline by Octapharma AG, H2 2016

Septic Shock - Pipeline by Orion Oyj, H2 2016

Septic Shock - Pipeline by Peptinov SAS, H2 2016

Septic Shock - Pipeline by Pharmazz, Inc., H2 2016

Septic Shock - Pipeline by Spider Biotech, H2 2016

Septic Shock - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016

Septic Shock - Pipeline by Therashock, LLC, H2 2016

Septic Shock - Pipeline by ViiV Healthcare Limited, H2 2016

Septic Shock - Pipeline by XImmune AB, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Septic Shock - Dormant Projects, H2 2016

Septic Shock - Dormant Projects (Contd..1), H2 2016

Septic Shock - Discontinued Products, H2 2016 85List of Figures

Number of Products under Development for Septic Shock, H2 2016

Number of Products under Development for Septic Shock - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Adrenomed AG
  • InflaRx GmbH
  • Noxxon Pharma AG
  • Orion Oyj
  • Pharmazz, Inc.
  • Therashock, LLC
  • MORE
Septic Shock Septic shock is a serious condition that occurs when an overwhelming infection leads to life-threatening low blood pressure. Septic shock occurs most often in the very old and the very young. Any type of bacteria can cause septic shock. Fungi and (rarely) viruses may also cause the condition. Toxins released by the bacteria or fungi may cause tissue damage, and may lead to low blood pressure and poor organ function. Symptoms include patches of discolored skin, confusion, chills due to fall in body temperature, extreme weakness or lightheadedness.

Septic Shock pipeline therapeutics constitutes close to 29 molecules. Out of which approximately 26 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 2, 14, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Our latest report Septic Shock – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Septic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Septic Shock and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Adrenomed AG
Ferring International Center S.A.
Huons Co., Ltd.
InflaRx GmbH
Inotrem S.A.
Lixte Biotechnology Holdings, Inc.
Noxxon Pharma AG
Octapharma AG
Orion Oyj
Peptinov SAS
Pharmazz, Inc.
Spider Biotech
Takeda Pharmaceutical Company Limited
Therashock, LLC
ViiV Healthcare Limited
XImmune AB
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll